Another study reported that blockade of CXCR4/CXCL12 signaling with Plerixafor could also alleviate the desmoplasia and immunosuppression, in turn decompressing tumor vessels and increasing T cell infiltration, eventually enhancing immunotherapy in cold breast tumors [177]. Here, CXCL12 is linked to neoplasm.